TNX-102 SL (TONMYA)
Acute Stress Disorder (ASD)
Phase 2Enrolling; Topline data expected 2H 2026
Key Facts
Indication
Acute Stress Disorder (ASD)
Phase
Phase 2
Status
Enrolling; Topline data expected 2H 2026
Company
About Tonix Pharmaceuticals
Tonix Pharmaceuticals is a patient-focused biotechnology company dedicated to developing impactful treatments for complex, chronic conditions that defy easy answers, including nociplastic pain, immunology/immuno-oncology, and infectious diseases. Its strategy leverages an integrated clinical development engine to advance a diverse pipeline, with key programs like TNX-102 SL for acute stress disorder expected to report Phase 2 topline data in the second half of 2026. The company's mission is to empower patients to live fully through scientific rigor and a deep respect for the patient experience, supported by a leadership team with significant industry expertise.
View full company profile